PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
27533887-9	2016	Electrophysiological data revealed a reversible inhibitory effect of Hcrt on GnRH3 neuron electrical activity, which was blocked by the HcrtR antagonist almorexant.	almorexant	153-163	hypocretin (orexin) neuropeptide precursor	Danio rerio	69-73
28364509-0	2017	Dual Orexin Receptor Antagonist, Almorexant, in Elderly Patients With Primary Insomnia: A Randomized, Controlled Study.	almorexant	33-43	hypocretin neuropeptide precursor	Homo sapiens	5-11
27533887-9	2016	Electrophysiological data revealed a reversible inhibitory effect of Hcrt on GnRH3 neuron electrical activity, which was blocked by the HcrtR antagonist almorexant.	almorexant	153-163	gonadotropin-releasing hormone 3	Danio rerio	77-82
27533887-9	2016	Electrophysiological data revealed a reversible inhibitory effect of Hcrt on GnRH3 neuron electrical activity, which was blocked by the HcrtR antagonist almorexant.	almorexant	153-163	hypocretin (orexin) receptor 2	Danio rerio	136-141
26174505-2	2015	Disinhibition of this area in the anaesthetized preparation evokes cardiorespiratory changes that can be reduced to nearly half or more by systemic Almorexant, a dual receptor antagonist of the two known orexin receptors, Ox1R and Ox2R.	almorexant	148-158	hypocretin receptor 2	Rattus norvegicus	231-235
26174505-2	2015	Disinhibition of this area in the anaesthetized preparation evokes cardiorespiratory changes that can be reduced to nearly half or more by systemic Almorexant, a dual receptor antagonist of the two known orexin receptors, Ox1R and Ox2R.	almorexant	148-158	hypocretin neuropeptide precursor	Rattus norvegicus	204-210
27384072-7	2016	The dual orexin receptor blocker, Almorexant, attenuated the effect of sympathetic long-term facilitation generated by intermittent orexin-A (20.7% +- 4.5% for Almorexant at 30 mg kg(-1) and 18.5% +- 1.2% for 75 mg kg(-1)), but not in AIH.	almorexant	34-44	hypocretin neuropeptide precursor	Rattus norvegicus	9-15
27384072-7	2016	The dual orexin receptor blocker, Almorexant, attenuated the effect of sympathetic long-term facilitation generated by intermittent orexin-A (20.7% +- 4.5% for Almorexant at 30 mg kg(-1) and 18.5% +- 1.2% for 75 mg kg(-1)), but not in AIH.	almorexant	34-44	hypocretin neuropeptide precursor	Rattus norvegicus	132-140
27384072-7	2016	The dual orexin receptor blocker, Almorexant, attenuated the effect of sympathetic long-term facilitation generated by intermittent orexin-A (20.7% +- 4.5% for Almorexant at 30 mg kg(-1) and 18.5% +- 1.2% for 75 mg kg(-1)), but not in AIH.	almorexant	160-170	hypocretin neuropeptide precursor	Rattus norvegicus	132-140
25431268-2	2016	The dual HCRT receptor antagonist almorexant (ALM) decreases waking and increases sleep.	almorexant	34-44	hypocretin neuropeptide precursor	Rattus norvegicus	9-13
22990330-0	2013	Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.	almorexant	32-42	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	79-85
25085886-8	2014	injections of almorexant (100 mg kg(-1)), a dual orexin receptor antagonist.	almorexant	14-24	hypocretin neuropeptide precursor	Rattus norvegicus	49-55
24574958-10	2014	Treating SHRs by blocking both orexin receptors with oral administration of an antagonist, almorexant (Almxt), can normalize the CO2 chemoreflex and significantly lower ABP and SNA.	almorexant	91-101	hypocretin	Mus musculus	31-37
24574958-10	2014	Treating SHRs by blocking both orexin receptors with oral administration of an antagonist, almorexant (Almxt), can normalize the CO2 chemoreflex and significantly lower ABP and SNA.	almorexant	103-108	hypocretin	Mus musculus	31-37
24880753-7	2014	Almorexant increased the exposure to desipramine 3.7-fold, suggesting that almorexant is a moderate inhibitor of desipramine metabolism through inhibition of CYP2D6.	almorexant	75-85	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	158-164
22990330-1	2013	PURPOSE: Pre-clinical experiments have shown that almorexant, a dual orexin receptor antagonist, is able to inhibit cytochrome P450 3A4 (CYP3A4).	almorexant	50-60	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	116-135
22990330-1	2013	PURPOSE: Pre-clinical experiments have shown that almorexant, a dual orexin receptor antagonist, is able to inhibit cytochrome P450 3A4 (CYP3A4).	almorexant	50-60	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	137-143
23019212-0	2012	Blockade of orexin receptors with Almorexant reduces cardiorespiratory responses evoked from the hypothalamus but not baro- or chemoreceptor reflex responses.	almorexant	34-44	hypocretin neuropeptide precursor	Rattus norvegicus	12-18
22658401-0	2013	Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humans.	almorexant	35-45	hypocretin neuropeptide precursor	Homo sapiens	5-11
23204605-0	2012	The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors.	almorexant	36-46	hypocretin	Mus musculus	9-15
23204605-0	2012	The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors.	almorexant	36-46	hypocretin	Mus musculus	75-81
23204605-0	2012	The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors.	almorexant	36-46	hypocretin	Mus musculus	75-81
22768296-12	2012	HCRTR1 occupancy by almorexant declined 4-6 h post-administration while HCRTR2 occupancy was still elevated after 12 h, revealing a complex relationship between occupancy of HCRT receptors and sleep promotion.	almorexant	20-30	hypocretin receptor 1	Rattus norvegicus	0-6
23028593-6	2012	Extracellular recordings performed in VTA neurons revealed that orexin-A increased firing and this enhancement of firing was blocked by almorexant.	almorexant	136-146	hypocretin neuropeptide precursor	Homo sapiens	64-70
20047164-0	2010	Almorexant, a dual orexin receptor antagonist for the treatment of insomnia.	almorexant	0-10	hypocretin neuropeptide precursor	Homo sapiens	19-25
20177882-6	2010	RESULTS: The hcrtR1 antagonist SB334867 and the hcrtR1/2 antagonist almorexant both reduced NSA dose-dependently (significantly at doses of 30 and 300 mg/kg, respectively); SB334867 did not affect food-maintained responding whereas almorexant (at the 300 mg/kg) did.	almorexant	68-78	hypocretin receptor 1	Rattus norvegicus	48-56
19542319-5	2009	In Schild analyses using the [(3)H]inositol phosphates assay, almorexant acted as a competitive antagonist at hOX(1) and as a noncompetitive-like antagonist at hOX(2).	almorexant	62-72	homeobox A5	Homo sapiens	110-116
19542319-5	2009	In Schild analyses using the [(3)H]inositol phosphates assay, almorexant acted as a competitive antagonist at hOX(1) and as a noncompetitive-like antagonist at hOX(2).	almorexant	62-72	CD200 molecule	Homo sapiens	160-166